# Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study

> **NCT05056194** · PHASE2 · WITHDRAWN · sponsor: **XWPharma**

## Conditions studied

- Parkinson Disease
- Excessive Daytime Somnolence

## Interventions

- **DRUG:** Valiloxybate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05056194
- **Lead sponsor:** XWPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11-01
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05056194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05056194, "Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05056194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*